GH Research (NASDAQ:GHRS) Reaches New 52-Week High – What’s Next?

Posted by Stanley Muller on Jun 26th, 2026

GH Research PLC (NASDAQ:GHRS – Get Free Report) shares hit a new 52-week high on Friday . The company traded as high as $26.35 and last traded at $26.2650, with a volume of 24293 shares trading hands. The stock had previously closed at $25.34.

Analyst Ratings Changes

A number of research firms have recently commented on GHRS. Guggenheim set a $34.00 price objective on GH Research and gave the stock a “buy” rating in a report on Tuesday, March 10th. HC Wainwright lowered their price target on GH Research from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Cantor Fitzgerald boosted their price target on GH Research from $25.00 to $35.00 and gave the company an “overweight” rating in a research report on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a report on Tuesday, April 21st. Finally, Needham & Company LLC lifted their price objective on GH Research from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.38.

Get Our Latest Report on GHRS

GH Research Stock Up 7.7%

The firm’s 50 day moving average price is $21.49 and its two-hundred day moving average price is $17.21. The firm has a market capitalization of $1.87 billion, a PE ratio of -29.70 and a beta of 1.31.

GH Research (NASDAQ:GHRS – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). On average, sell-side analysts anticipate that GH Research PLC will post -1.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. HighVista Strategies LLC boosted its holdings in GH Research by 363.0% in the third quarter. HighVista Strategies LLC now owns 241,894 shares of the company’s stock worth $3,459,000 after purchasing an additional 189,647 shares during the period. Avoro Capital Advisors LLC acquired a new position in shares of GH Research during the fourth quarter worth approximately $22,860,000. CenterBook Partners LP boosted its position in shares of GH Research by 70.6% during the fourth quarter. CenterBook Partners LP now owns 283,441 shares of the company’s stock worth $3,600,000 after buying an additional 117,288 shares during the period. BIT Capital GmbH bought a new position in GH Research in the 4th quarter worth approximately $635,000. Finally, Troluce Capital Advisors LLC grew its holdings in GH Research by 165.4% in the 1st quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock worth $13,926,000 after buying an additional 617,260 shares in the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

(Get Free Report)

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.